Adopting NICE guidance to deliver evidence-based outcomes and recognise local value made easy

Evidence isn’t just nice to have. It is crucial, as reflected recently by the Association of British HealthTech Industries:

“The covid-19 crisis has demonstrated the critical role HealthTech plays in the protection and treatment of our citizens. Never has the value, rather than the price of technology, been so well appreciated, and the outcomes achieved by using technology to deliver care been so highly prized.”

In the UK, one in seven adults is affected by constipation, and research shows chronic constipation is causing people to suffer in silence, leading to 76,929 hospital admissions in 2018-19 and costing over £100m a year. Whilst effective bowel management is imperative for these individuals, chronic constipation poses a significant health burden.

Peristeen® Plus is the only transanal irrigation device with NICE guidance. Yet, adopting the Medical Technologies Guidance for Coloplast’s transanal irrigation device remains varied across the UK, leading to unwarranted variation due to local practice.

Peristeen® Plus is a cost-effective device for optimising bowel dysfunction and reducing the clinical and cost burden that faecal incontinence and chronic constipation can bring

Peristeen® Plus can directly benefit patients and carers whilst reducing costs for healthcare providers. The device has been helping people better manage their condition, and successful implementation of the guidance has been found to support cost savings by reducing the need for avoidable healthcare visits and fewer hospitalisations.

By treating patients with chronic constipation and faecal incontinence more effectively, Peristeen® Plus has also been shown to reduce the incidence of urinary tract infections, freeing up time for carers and decreasing the additional costs associated with managing recurring episodes of faecal incontinence. This combination of factors led NICE to advise the NHS adoption of Peristeen® Plus, which could facilitate savings of £5,144 per patient over the average length of lifetime treatment.

At a time when healthcare resources are challenged, it’s important to see the updated NICE guidance reaffirming that, used routinely, Peristeen® Plus is a cost-effective device for optimising bowel dysfunction and reducing the clinical and cost burden that faecal incontinence and chronic constipation can bring.

Coloplast has developed a new budget impact tool that enables, at a local level, an exploration of what impact increasing Peristeen® Plus could have and how to recognise these savings.

The model can visually depict current spending from local ICB populations with bowel dysfunction and support scenario planning for the uptake of Peristeen® Plus across an appropriate cohort of patients.

Using this tool can help a local commissioning organisation demonstrate the efficiencies that can be realised and how these align with local priorities accordingly.

For further information about this model or to request a demonstration for your locality, please contact Angela Crossland at GBACS@coloplast.com or +44 (0) 7703477314.

Making life easier for people with deeply private bladder and bowel conditions is in Coloplast’s DNA. Striving to make a difference, we remain committed, dedicating time and resources to fully understand patients’ conditions, and their impact on quality of life to develop solutions specific to patients’ needs.